Clinic launch guide

Adding 503A Compounded Peptides

Reviewed by ExaVeyra Sciences editorial team · Updated 16 August 2026

A compounded peptide reaches a patient lawfully when the bulk substance it was made from qualifies under section 503A of the Federal Food, Drug, and Cosmetic Act, and there are three separate ways for a substance to qualify. Most practitioners have only heard of one of them, which is why so many conversations about peptides stall on the question of whether something is "on the list" when the list is the third route rather than the only one.

Understanding all three changes what a practice can plan. It explains why some peptide preparations have been dispensed routinely for years, why others are not available from a compounding pharmacy at any price, and what would have to happen for that to change. This page sets out the three routes, shows where the well-known peptides currently sit, and explains what the July 2026 advisory committee vote actually did.

The three routes a bulk substance can qualify

FDA states the rule directly. State-licensed physicians and pharmacists compounding under section 503A may only compound using bulk drug substances that meet one of the following.

Two further requirements apply on top of whichever route a substance takes, and they are the ones a purchasing practice can verify directly. The bulk drug substance must be accompanied by a valid certificate of analysis, and it must have been manufactured by an establishment registered with FDA under section 510 of the Act. FDA’s own phrasing on this is worth adopting as a purchasing habit: know your bulks supplier.

How the 503A bulks list has been built

FDA solicited nominations in 2015 and has been working through them since, consulting the Pharmacy Compounding Advisory Committee and the US Pharmacopeial Convention. A final regulation issued in February 2019 placed six substances on the list, declined four, and set the criteria for evaluating the rest. A proposed regulation in September 2019 proposed placing five more and declining twenty-six. FDA continues to evaluate sufficiently supported nominations on a rolling basis through notice-and-comment rulemaking.

Because that process takes time, FDA also published an interim policy describing three categories of nominated substances and the enforcement posture attached to each. The categories are not the bulks list. They describe how FDA intends to act while a nomination is pending.

• Category 1: nominated with sufficient supporting information, may be eligible for the list, and not on any other list. FDA does not intend to take action against a compounder using these, provided the conditions in the guidance are met.
• Category 2: nominated with sufficient information, but FDA has identified significant safety risks pending further evaluation. FDA publishes the safety information for each and would consider action under its general enforcement policies.
• Category 3: nominated with insufficient supporting information for FDA to evaluate. These can be re-nominated with fuller information.

One update is frequently misreported, so it is worth stating precisely. FDA issued guidance revising the application of this policy, and that guidance says the agency does not intend to place substances nominated on or after 7 January 2025 into these categories. Substances already placed in a category remain where they are. Category 1 substances may continue within the interim enforcement policy until FDA decides on their inclusion on the bulks list, or until the agency removes them from category 1 on the basis of new safety information.

Where the well-known peptides sit today

On FDA’s Safety Risks page, currency date 22 April 2026, the following peptides appear in the category 2 table, each with FDA’s stated rationale: BPC-157, thymosin beta-4 fragment (LKKTETQ), also known as TB-500, KPV, MOTs-C, epitalon, semax, ipamorelin, CJC-1295, thymosin-alpha 1, GHK-Cu for injectable routes, selank acetate, cathelicidin LL-37, PEG-MGF, GHRP-2 and GHRP-6. The recurring themes in FDA’s reasoning are worth reading in the agency’s own words rather than in summary.

• On BPC-157: compounded drugs containing it "may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization", and FDA "has identified no, or only limited, safety-related information for the proposed routes of administration".
• On KPV: FDA "has not identified any human exposure data on drug products containing KPV administered via any route of administration".
• On thymosin beta-4 fragment (TB-500): FDA "has not identified any human exposure data" for it and "lacks important information regarding any safety issues raised by this drug".
• On MOTs-C and on epitalon: the same pattern of immunogenicity and characterisation complexity, with no or limited human safety data identified for the proposed routes.

Two things follow. A pharmacy declining to prepare one of these is applying FDA’s published position rather than being unhelpful. And the gap FDA describes is an evidence gap, which is the kind of gap that closes when studies are run. Our peptide evidence pages set out, molecule by molecule, exactly how far the published literature has got.

What the July 2026 advisory vote did

The Pharmacy Compounding Advisory Committee met on 23 and 24 July 2026 to consider seven peptide-related bulk substances for the 503A bulks list. On 23 July it took up BPC-157, KPV, TB-500 and MOTs-C; on 24 July, emideltide (also referred to as delta sleep-inducing peptide), semax and epitalon. The committee recommended six of the seven for inclusion and recommended against emideltide.

What that vote is, precisely: advice. The committee advises FDA and its recommendations are not binding. Adding a substance to the 503A bulks list happens through notice-and-comment rulemaking, which is a separate and slower process. Until a substance is actually placed on the list by rule, its status is whatever FDA’s current lists say it is.

Patient-specific dispensing, and where office stock comes from

A 503A pharmacy compounds against a prescription for an identified individual patient. That is the defining feature of the section, and it shapes how a practice orders. Office stock, meaning product held on the shelf before a patient is identified, comes from a 503B outsourcing facility instead. Outsourcing facilities may compound larger batches with or without patient-specific prescriptions and must comply with current good manufacturing practice.

Neither is better than the other. They are two supply models for two different clinical patterns, and many practices use both: a 503B relationship for what is administered in the room, a 503A relationship for individualised strengths a patient takes home. Our dedicated comparison covers the differences in detail, including what each is permitted to do about beyond-use dating and interstate distribution.

Beyond-use dating and storage

Compounded preparations carry a beyond-use date rather than an expiration date, and the two are set by different logic. USP General Chapter 795 governs nonsterile preparations and 797 governs sterile preparations, with revised versions of both official from 1 November 2023. The 797 revision replaced the older low, medium and high risk levels with Category 1, 2 and 3 preparations, each carrying its own dating limits, and added Category 3 to describe what a facility must maintain to assign beyond-use dates as long as 180 days.

For a clinic, the useful consequence is that a longer beyond-use date reflects a higher standard maintained at the pharmacy rather than a more stable molecule. Asking which USP category a preparation was made under tells you more about a pharmacy than asking how long the product lasts.

A short checklist before the first order

• Ask which of the three 503A routes each substance qualifies under, and ask the pharmacy to say so in writing.
• Request the certificate of analysis for the bulk substance, and confirm the manufacturing establishment is registered with FDA under section 510.
• Confirm whether you are buying patient-specific from a 503A or office stock from a 503B, and that your ordering workflow matches.
• Ask which USP chapter and category the preparation is made under, and what beyond-use date follows.
• Confirm storage and shipping conditions, and write the receiving check into a standard operating procedure.
• Check the state board of pharmacy rules that apply to shipments into your state, which can be stricter than the federal floor.

Sources

1. FDA, Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (accessed 16 August 2026)
2. FDA, Safety Risks Associated with Certain Bulk Drug Substances Nominated for Use in Compounding (category 2 table) (accessed 16 August 2026)
3. FDA, Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the FD&C Act: Guidance for Industry (accessed 16 August 2026)
4. FDA, Meeting of the Pharmacy Compounding Advisory Committee, 23 to 24 July 2026 (accessed 16 August 2026)
5. FDA, Human Drug Compounding: Compounding and the FD&C Act questions and answers (accessed 16 August 2026)
6. FDA, Information for Outsourcing Facilities (section 503B) (accessed 16 August 2026)
7. FDA, Registered Outsourcing Facilities (accessed 16 August 2026)
8. FDA, Drug Establishments Current Registration Site (accessed 16 August 2026)